Juan Zhang
Research Subjects
Juan Zhang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Chunling Li
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
28 shared publications - Chunyan Wang
Department of Biochemistry and Molecular Biology, Shandong Tumor Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, P.R. China
28 shared publications - Dapeng Wang
School of Basic Medicine, Bengbu Medical University
28 shared publications - Fangmin Li
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
28 shared publications - Feng Kong
Department of Central Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
28 shared publications - Hongying Wang
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
28 shared publications
Latest Publications
- 8 July 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 218, 108692
The β4-β5 loop and C-SH2 domain mediate the unique ability of SHP1 to dephosphorylate CagA and counteract Helicobacter pylori-induced pathogenesis
- 8 July 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 218, 108692
The β4-β5 loop and C-SH2 domain mediate the unique ability of SHP1 to dephosphorylate CagA and counteract Helicobacter pylori-induced pathogenesis
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
THP-1-igsf9-WT not -igsf9-KO cells inhibited T cell proliferation in vitro.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
THP-1-igsf9-WT not -igsf9-KO cells inhibited T cell proliferation in vitro.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 reversed the inhibition of T cells mediated by IGSF9-ECD.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 reversed the inhibition of T cells mediated by IGSF9-ECD.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in normal tissue array.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in normal tissue array.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in tumor tissue arrays by immunohistochemistry.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in tumor tissue arrays by immunohistochemistry.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Supplementary material and methods and Supplementary tables
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Supplementary material and methods and Supplementary tables
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 regained the activation of T cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 regained the activation of T cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Mouse IGSF9 was detected before and after MC38 implantation.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Mouse IGSF9 was detected before and after MC38 implantation.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 itself did not affect tumor cell proliferation.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 itself did not affect tumor cell proliferation.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Human IGSF9 was detected in myeloid cells of peripheral blood from healthy donors and tumor patients.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Human IGSF9 was detected in myeloid cells of peripheral blood from healthy donors and tumor patients.